Cargando…
Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells
BACKGROUND: TP53 mutations in cancer cells often evoke cell invasiveness, whereas fibroblasts show invasiveness in the presence of intact TP53. AMAP1 (also called DDEF1 or ASAP1) is a downstream effector of ARF6 and is essential for the ARF6-driven cell-invasive phenotype. We found that AMAP1 levels...
Autores principales: | Handa, Haruka, Hashimoto, Ari, Hashimoto, Shigeru, Sugino, Hirokazu, Oikawa, Tsukasa, Sabe, Hisataka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278066/ https://www.ncbi.nlm.nih.gov/pubmed/30509302 http://dx.doi.org/10.1186/s12964-018-0302-6 |
Ejemplares similares
-
Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
por: Otsuka, Yutaro, et al.
Publicado: (2018) -
Necessity of p53-binding to the CDH1 locus for its expression defines two epithelial cell types differing in their integrity
por: Oikawa, Tsukasa, et al.
Publicado: (2018) -
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
por: Tsutaho, Akio, et al.
Publicado: (2020) -
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2016) -
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)